Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
TOWA Pharmaceutical CoTWAPF 79 EV-to-EBITDA is 9.23 as of Aug. 01, 2026, which is 11% below its 10-year median of 10.34. GuruFocus rates TWAPF with a GF Score™ of 79/100 and a GF Value™ of $14.19 (Significantly Overvalued). The stock has 10 warning signs investors should review. Among 747 Drug Manufacturers companies, TOWA Pharmaceutical Co ranks better than 61.98% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, TOWA Pharmaceutical Co's enterprise value is $2,360 Mil.
TOWA Pharmaceutical Co's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $256 Mil. Therefore, TOWA Pharmaceutical Co's EV-to-EBITDA for today is 9.23.
The historical rank and industry rank for TOWA Pharmaceutical Co's EV-to-EBITDA or its related term are showing as below:
TWAPF'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.3 Med: 10.34 Max: 44.46
Current: 9.3
During the past 13 years, the highest EV-to-EBITDA of TOWA Pharmaceutical Co was 44.46. The lowest was 6.30. And the median was 10.34.
TWAPF's EV-to-EBITDA is ranked better than 61.98% of 747
companies
in the Drug Manufacturers industry
Industry Median: 12.88
vs TWAPF: 9.30
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
TOWA Pharmaceutical Co (OTCPK:TWAPF) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
TOWA Pharmaceutical Co's PE Ratio (TTM) for today is calculated as:
TOWA Pharmaceutical Co's share price for today is $25.98.
TOWA Pharmaceutical Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.776.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, TOWA Pharmaceutical Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TOWA Pharmaceutical Co EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, TOWA Pharmaceutical Co's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where TOWA Pharmaceutical Co's EV-to-EBITDA falls into.
TOWA Pharmaceutical Co's current Enterprise Value is $2,360 Mil.
TOWA Pharmaceutical Co's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $256 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TOWA Pharmaceutical Co (TWAPF) has a EV-to-EBITDA of 9.23 as of Aug. 01, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on TOWA Pharmaceutical Co. This is 11% below median its historical median of 10.34. Over the past decade, TOWA Pharmaceutical Co's EV-to-EBITDA has ranged from 6.30 to 44.46. According to the industry distribution chart, TOWA Pharmaceutical Co ranks #284 out of 747 companies in the Drug Manufacturers industry, placing it in the top 38%.
Is TOWA Pharmaceutical Co's EV-to-EBITDA too high?
TOWA Pharmaceutical Co's current EV-to-EBITDA of 9.23 is 11% below median its 10-year median of 10.34. Over the past 10 years, this metric has ranged from a low of 6.30 to a high of 44.46. The Drug Manufacturers industry median EV-to-EBITDA is 12.88. TOWA Pharmaceutical Co's value of 9.23 is 28.3% below this industry median. Based on the distribution chart, TOWA Pharmaceutical Co ranks #284 out of 747 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, TOWA Pharmaceutical Co has a GF Score™ of 79/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does TOWA Pharmaceutical Co's EV-to-EBITDA compare to ZTS?
According to the Drug Manufacturers industry distribution chart, TOWA Pharmaceutical Co ranks #284 out of 747 companies for EV-to-EBITDA. This puts TOWA Pharmaceutical Co in the upper half of its industry. The industry median EV-to-EBITDA is 12.88. TOWA Pharmaceutical Co's value of 9.23 is 28.3% below this benchmark. Historically, TOWA Pharmaceutical Co's own EV-to-EBITDA has ranged from 6.30 to 44.46 over the past decade. While the company's 10-year median is 10.34 vs. the industry median of 12.88, TOWA Pharmaceutical Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 12.88, based on 747 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. TOWA Pharmaceutical Co's current EV-to-EBITDA of 9.23 is 28.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on TOWA Pharmaceutical Co. For the Drug Manufacturers industry, the median EV-to-EBITDA is 12.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TOWA Pharmaceutical Co's current EV-to-EBITDA is 9.23, which is 11% below median its own 10-year median of 10.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TOWA Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, TOWA Pharmaceutical Co (TWAPF) is currently considered Significantly Overvalued. The stock's GF Value™ is $14.19, compared to a current price of $25.98 — trading 83.1% above its estimated fair value. The current EV-to-EBITDA is 9.23, which is 11% below median its 10-year median of 10.34 and 28.3% below the Drug Manufacturers industry median of 12.88. TOWA Pharmaceutical Co's overall GF Score™ is 79/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For TOWA Pharmaceutical Co (TWAPF), the current EV-to-EBITDA is 9.23 as of Aug. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is TOWA Pharmaceutical Co (TWAPF) Overvalued in 2026?
Based on GuruFocus' analysis, TOWA Pharmaceutical Co stock appears to be overvalued.
The current stock price of $25.98 is trading 83.1% above its estimated GF Value™ of $14.19.
GuruFocus considers TOWA Pharmaceutical Co to be Significantly Overvalued.
Key valuation signals for TWAPF:
EV-to-EBITDA: 9.23 (11% below median its 10-year median of 10.34)
GF Value™: $14.19 vs. price of $25.98 (83.1% above fair value)
Industry Position: 28.3% below the Drug Manufacturers median (#284 of 747)
No single metric tells the full story. See the TWAPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
TOWA Pharmaceutical Co Ltd is a Japan based pharmaceutical company engaged in research and development, production, and marketing of generic drugs. It also provides drug consulting services for patients and their families and relatives. It organizes academic seminars for medical professionals and posts articles in journals. It participates in training for pharmacists. The company has three main plants in operation namely Osaka plant, Okayama plant, and Yamagata plant. Towa has offers more than 500 drugs to meet the diverse therapeutic requirements including lifestyle related diseases such as hypertension and diabetes, digestive system diseases, nervous system diseases and allergic diseases, vitamins and antibiotics.
79GF Score
Get the complete analysis for TWAPF
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TWAPF has been successfully added to your 
